<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00080626</url>
  </required_header>
  <id_info>
    <org_study_id>J0266</org_study_id>
    <secondary_id>P50CA088843</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>NA_00040559</secondary_id>
    <secondary_id>JHOC-03012301</secondary_id>
    <secondary_id>JHOC-J0266</secondary_id>
    <secondary_id>CDR0000346460</secondary_id>
    <nct_id>NCT00080626</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer</brief_title>
  <official_title>A Pilot Study Assessing Patterns of Response or Resistance to Preoperative Dose Dense Docetaxel in Women With Newly Diagnosed Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before&#xD;
      surgery may shrink the tumor so that it can be removed.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well neoadjuvant docetaxel works in treating&#xD;
      women who are undergoing surgery for breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Correlate baseline and change in apoptosis and proliferation with clinical and&#xD;
           pathological response to neoadjuvant docetaxel followed by surgery in women with newly&#xD;
           diagnosed breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Correlate baseline and change in fludeoxyglucose F 18 positron emission tomography&#xD;
           uptake with clinical and pathological response in patients treated with this regimen.&#xD;
&#xD;
        -  Correlate baseline and change in gene expression profiles with clinical and pathological&#xD;
           response in patients treated with this regimen.&#xD;
&#xD;
        -  Correlate baseline and change in tumor and serum proteomic patterns with clinical and&#xD;
           pathological response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
        -  Neoadjuvant chemotherapy: Patients receive docetaxel IV over 1 hour on day 1 and&#xD;
           pegfilgrastim subcutaneously (SC) on day 2. Treatment repeats every 14 days for 4&#xD;
           courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Surgery: Within 2-4 weeks after the completion of 4 courses of docetaxel, patients&#xD;
           undergo breast-conserving surgery or a mastectomy at the discretion of the treating&#xD;
           surgeon. Patients may receive additional chemotherapy prior to surgery at the discretion&#xD;
           of the treating physician.&#xD;
&#xD;
        -  Adjuvant chemotherapy: Patients receive adjuvant chemotherapy at the discretion of the&#xD;
           treating physician.&#xD;
&#xD;
        -  Radiotherapy: Patients undergo radiotherapy after the completion of all chemotherapy at&#xD;
           the discretion of the treating physician.&#xD;
&#xD;
        -  Hormonal therapy: Patients with estrogen- and/or progesterone-positive tumors receive&#xD;
           hormonal therapy after the completion of chemotherapy and all local therapies at the&#xD;
           discretion of the treating physician.&#xD;
&#xD;
      Patients are followed every 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date type="Actual">August 11, 2003</start_date>
  <completion_date type="Actual">May 1, 2006</completion_date>
  <primary_completion_date type="Actual">May 1, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between change in apoptosis and proliferation with response after definitive surgery</measure>
    <time_frame>Definitive surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between change in fludeoxyglucose F 18 positron emission tomography uptake with response after definitive surgery</measure>
    <time_frame>Definitive surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant therapy with docetaxel (IV, 100 mg/m2, every 14 days with growth factor support with pegfilgrastim) for a total of 4 cycles prior to conventional surgery for breast cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
    <description>6 mg injection on day 1 of each cycle</description>
    <arm_group_label>Docetaxel</arm_group_label>
    <other_name>Neulasta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>100 mg per meter-squared, every 14 days for 4 cycles</description>
    <arm_group_label>Docetaxel</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>lumpectomy or mastectomy at end of treatment</description>
    <arm_group_label>Docetaxel</arm_group_label>
    <other_name>definitive surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <description>treatment prior to definitive breast surgery</description>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed infiltrating carcinoma of the breast&#xD;
&#xD;
               -  Unresected clinical stage T1c, T2, T3, or T4 lesion, any N&#xD;
&#xD;
          -  Newly diagnosed disease&#xD;
&#xD;
               -  Diagnostic mammogram and an ultrasound of the affected breast within 3 months&#xD;
                  before study entry&#xD;
&#xD;
               -  Mammogram of the contralateral breast within 6 months before study entry&#xD;
&#xD;
          -  Clinically measurable disease&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Immunohistochemical staining for estrogen and progesterone and HER2/neu receptors&#xD;
                  must be obtained on initial diagnostic material&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 8 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times normal&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No medical condition that would put the patient at unnecessary risk of potentially&#xD;
             serious complications during study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for current breast cancer&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 1 month since prior tamoxifen or raloxifene for breast cancer prevention&#xD;
&#xD;
          -  No prior endocrine therapy for current breast cancer&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy for current breast cancer&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vered Stearns, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>April 7, 2004</study_first_submitted>
  <study_first_submitted_qc>April 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2004</study_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

